Wedbush Reiterates Buy Rating on VRDN with $43 Price Target
Wedbush maintains its buy rating on VRDN, setting a $43 price target, a 128.85% upside from the current price.
Key Points
- Wedbush reiterated its buy rating on VRDN, setting a price target of $43 as of June 30, 2026.
- Wedbush's $43 price target implies 128.85% upside from Viridian Therapeutics, Inc.'s ($VRDN) current $18.79 share price.
- VRDN shares traded at $18.79 on Tuesday, with institutional investors showing varied activity in the stock.
- Analysts from Needham and Wells Fargo also maintain positive outlooks, with price targets of $34 and $31, respectively.
Important disclosure: Podchat is not a registered investment adviser, broker-dealer, or financial planner. This article is for informational and educational purposes only and is not a recommendation to buy, sell, or hold any security. Content may be generated by automated systems using public filings, market data, and third-party sources, and may contain errors or omissions. Investing involves risk, including possible loss of principal. Past performance, insider activity, analyst ratings, price targets, sentiment scores, and hypothetical or backtested results are not guarantees of future performance. Please do your own research and consult a qualified professional before making investment decisions.
On June 30, 2026, Wedbush reaffirmed its buy rating for VRDN, setting a price target of $43. Shares of VRDN traded at $18.79 on Tuesday, reflecting the analyst's confidence in the stock's potential upside.
Wedbush vs. the S&P 500
Hypothetical, simulated performance of disclosed positions vs. the S&P 500. Not realized profit and not investment advice. Past performance does not indicate future results. Details.
Other Institutional Activity in VRDN
Several institutional investors have made significant moves in VRDN. FMR LLC increased its stake by 994,921 shares, ending with 15,379,377 shares valued at approximately $300.8 million, marking a 6.9% increase. BlackRock, Inc. added 1,399,552 shares, bringing its total to 7,831,475 shares worth about $153.2 million, a 21.8% rise. Bellevue Group AG boosted its holdings by 2,367,617 shares, reaching 6,726,144 shares valued at $131.6 million, a 54.3% increase. State Street Corp also increased its stake by 1,206,325 shares to 4,672,885 shares, valued at about $91.4 million, a 34.8% rise. Meanwhile, Vanguard Capital Management LLC opened a new position with 4,167,201 shares valued at $81.5 million.
Viridian Therapeutics, Inc. Stock Down 18.6%
Shares of VRDN traded at $18.79 on Tuesday. The stock has been actively traded by institutional investors, indicating a mix of confidence and strategic positioning. With analysts setting high price targets, the stock remains one to watch.
$VRDN price target
Past daily closes and this analyst's 12-month price target. Not investment advice.
Insider Buying and Selling at Viridian Therapeutics, Inc.
On May 11, 2026, Fairmount Funds Management LLC purchased 1,176,470 shares at an average price of $17. On March 3, 2026, several insiders, including Chief Legal Officer Jennifer Tousignant, Chief Operating Officer Thomas Beetham, Chief Financial Officer Seth Harmon, and President and CEO Stephen Mahoney, sold shares at an average price of $30.19.
Analysts Set New Price Targets
On June 30, 2026, Wedbush maintained its buy rating on VRDN with a $43 price target. The same day, Needham also maintained a buy rating, setting a $34 target. On June 29, 2026, Wells Fargo upgraded the stock to a buy with a $31 target. The consensus among analysts is positive, with a predominant buy recommendation and an average price target reflecting confidence in VRDN's future performance.
Bottom Line
Wedbush's reiterated buy rating and $43 price target for VRDN highlight the firm's positive outlook. Institutional investors have shown mixed activity, with some increasing their stakes and others initiating new positions. Analysts generally maintain a favorable view of VRDN, with several firms setting high price targets. As always, remember that 13F filings and analyst ratings are backward-looking and may not reflect current conditions.
Get Viridian Therapeutics, Inc. alerts
New 13F filings, insider trades, and analyst moves on $VRDN, sent to your inbox. Free, and you can unsubscribe anytime.
This instant news alert was generated by automated narrative technology and financial data from Podchat and public regulatory filings. It is for informational purposes only and is not financial advice.